• 1. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 2. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 3. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 4. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 5. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridinecarboxylic acids
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridinecarboxylic acids and derivatives Pyridinecarboxylic acids

Recent Advances in the Application of Methyl 5-Bromo-6-methylnicotinate (CAS: 1174028-22-8) in Chemical Biology and Pharmaceutical Research

Methyl 5-bromo-6-methylnicotinate (CAS: 1174028-22-8) has emerged as a key building block in medicinal chemistry and drug discovery due to its versatile reactivity and structural features. Recent studies have highlighted its importance as a precursor for the synthesis of various biologically active compounds, particularly in the development of kinase inhibitors and other therapeutic agents targeting cancer and inflammatory diseases.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the utility of methyl 5-bromo-6-methylnicotinate in the synthesis of novel Bruton's tyrosine kinase (BTK) inhibitors. The researchers utilized this compound as a starting material to develop a series of potent and selective BTK inhibitors with improved pharmacokinetic properties. The bromo and ester functional groups allowed for efficient derivatization through cross-coupling reactions and subsequent transformations.

In the field of agrochemical research, methyl 5-bromo-6-methylnicotinate has shown promise as an intermediate for developing new generation pesticides. A recent patent application (WO2023057421) disclosed its use in creating neonicotinoid analogs with enhanced insecticidal activity and reduced environmental impact. The structural flexibility of this compound enables modifications that can fine-tune the biological activity and physicochemical properties of the final products.

Significant progress has been made in optimizing synthetic routes for methyl 5-bromo-6-methylnicotinate. A 2024 publication in Organic Process Research & Development reported an improved, scalable synthesis with higher yields and reduced environmental footprint. The new protocol employs catalytic C-H bromination and minimizes the use of hazardous reagents, addressing both economic and sustainability concerns in industrial production.

Recent pharmacological studies have explored the metabolic fate of methyl 5-bromo-6-methylnicotinate-derived compounds. Research published in Drug Metabolism and Disposition (2024) investigated the esterase-mediated hydrolysis of related prodrugs, providing valuable insights for designing more stable derivatives with optimized drug delivery characteristics.

The compound's potential in PET radiopharmaceutical development has also been recognized. A research group at Massachusetts General Hospital recently reported (Journal of Nuclear Medicine, 2024) the successful incorporation of [¹¹C]-labeled methyl 5-bromo-6-methylnicotinate derivatives as imaging probes for neuroinflammation, demonstrating its versatility beyond traditional small molecule drug development.

Ongoing research continues to uncover new applications for methyl 5-bromo-6-methylnicotinate in chemical biology. Its unique structural features make it particularly valuable for fragment-based drug discovery and the development of targeted protein degraders (PROTACs), as evidenced by several recent preclinical studies in oncology and neurodegenerative diseases.

• 1198016-45-3(Methyl 5-bromo-6-(trifluoromethyl)-3-pyridinecarboxylate)
• 129477-21-0(ethyl 5-bromo-2-methylpyridine-3-carboxylate)
• 29681-44-5(methyl 5-bromopyridine-3-carboxylate)
• 20986-40-7(ethyl 5-bromopyridine-3-carboxylate)
• 698356-46-6(Ethyl 5-bromo-2,6-dimethylnicotinate)
• 1190862-70-4(Ethyl 5-bromo-6-methylnicotinate)
• 1215916-40-7(methyl 5-bromo-2-methylpyridine-3-carboxylate)
• 1190862-72-6(5-bromo-6-methylpyridine-3-carboxylic acid)
• 886372-03-8(methyl 4-bromo-6-methylpyridine-3-carboxylate)
• 93350-01-7(5-bromo-4,6-dimethyl-pyridine-3-carboxylic acid)